MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

MDT

86.38

+0.14%↑

113.77

-0.97%↓

VEEV

172.52

-1.27%↓

HQY

80.96

-2.52%↓

TLRY

6.45

-2.86%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

511.47 -4.17

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

504.13

Max

532.52

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+32.03% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 12B
Vorige openingsprijs	515.64
Vorige sluitingsprijs	511.47

Nieuwssentiment

By Acuity

34%

66%

95 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 apr 2026, 17:26 UTC

Belangrijke Nieuwsgebeurtenissen

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7 apr 2026, 23:55 UTC

Marktinformatie

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Market Talk Roundup: Latest on U.S. Politics

7 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7 apr 2026, 23:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 apr 2026, 23:42 UTC

Marktinformatie

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:37 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7 apr 2026, 23:15 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7 apr 2026, 23:04 UTC

Belangrijke Nieuwsgebeurtenissen

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7 apr 2026, 23:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 apr 2026, 23:03 UTC

Marktinformatie

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7 apr 2026, 23:01 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7 apr 2026, 22:58 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7 apr 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

7 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 apr 2026, 19:45 UTC

Marktinformatie

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7 apr 2026, 19:17 UTC

Belangrijke Nieuwsgebeurtenissen

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7 apr 2026, 19:16 UTC

Marktinformatie

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Global Energy Roundup: Market Talk

7 apr 2026, 19:07 UTC

Marktinformatie

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7 apr 2026, 18:41 UTC

Acquisities, Fusies, Overnames

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7 apr 2026, 18:40 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7 apr 2026, 18:39 UTC

Acquisities, Fusies, Overnames

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7 apr 2026, 18:24 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 17:08 UTC

Marktinformatie

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7 apr 2026, 16:21 UTC

Belangrijke Nieuwsgebeurtenissen

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7 apr 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

32.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 32.03%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

95 / 349 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.